



SPAFID  
CONNECT

Informazione Regolamentata n. 20106-29-2022	Data/Ora Ricezione 06 Aprile 2022 17:55:21	Euronext Star Milan
---	---	---------------------

Societa' : PHARMANUTRA  
Identificativo : 159950  
Informazione  
Regolamentata  
Nome utilizzatore : PHARMANUTRAN04 - Roberto Lacorte  
Tipologia : 1.1; 3.1  
Data/Ora Ricezione : 06 Aprile 2022 17:55:21  
Data/Ora Inizio : 06 Aprile 2022 17:55:22  
Diffusione presunta  
Oggetto : PR - PHARMANUTRA - Pubblicazione of list  
and documentation for  
shareholders'meeting

*Testo del comunicato*

Vedi allegato.

**PHARMANUTRA S.P.A.:****PUBLICATION OF PROPOSED RESOLUTIONS AND PRESENTATION OF THE LISTS OF CANDIDATES  
FOR APPOINTMENT TO THE BOARD OF STATUTORY AUDITORS****PUBLICATION OF OTHER SHAREHOLDER MEETING DOCUMENTATION**

Pisa, 6 April 2022 – With reference to the Shareholders' Meeting of Pharmanutra S.p.A. convened for April 27, 2022 at 15:00 (the "**Meeting**"), it is noted that on April 1, 2022 the shareholders adhering to the Shareholders' Agreement, holders of a total of 6,292,160 shares equal to 64.99% of the subscribed and paid-up capital of Pharmanutra SpA - following the list for the appointment of the supervisory body filed by them on 1 April 2022 - presented, within the terms and in the manner prescribed by law, the proposed resolutions relating to points 3.2 and 3.4 on the agenda of the 'Assembly and therefore the appointment of the Chairman of the Board of Statutory Auditors and the remuneration of the Board of Statutory Auditors.

The list presented includes the following candidates:

Candidates for the office of Standing Auditor

1. Giuseppe Rotunno
2. Debora Mazzaccherini
3. Michele Giordano

Candidates for the office of Alternate Auditor

1. Elena Pro
2. Alessandro Lini

The list of candidates for the appointment of the members of the Board of Statutory Auditors presented by the aforementioned shareholders adhering to the Shareholders' Agreement, together with the documentation required pursuant to the law and the Articles of Association, and the proposed resolutions presented by the same shareholders are available to the public at the headquarters of the Company, in Pisa (PI), Via delle Lenze n. 216 / b, on the website at [www.pharmanutra.it](http://www.pharmanutra.it) (Corporate Governance Section - Shareholders' Meeting), as well as at the authorized storage mechanism eMarket Storage at [www.emarketstorage.com](http://www.emarketstorage.com).

Pharmanutra S.p.A. also announces that the Directors' Report on point no. 4 of the agenda of the Shareholders' Meeting, as well as the Report on the remuneration policy and remuneration paid drawn up pursuant to Articles 123-ter of the Legislative Decree. 58/1998 and 84-quater of Consob Regulation no. 11971/1999, are available at the registered office in Pisa, via delle Lenze 216 / b, on the Company's website [www.pharmanutra.it](http://www.pharmanutra.it) in the Governance / Shareholders' Meeting section, as well as at the authorized storage mechanism "eMarket Storage" which can be consulted at website [www.emarketstorage.com](http://www.emarketstorage.com).

The documentation referred to Art. 77, paragraph 2-bis, of Consob Regulation no. 11971/1999 will be made available to the public at the Company's registered office in accordance with the law.

*Per maggiori informazioni / For further information:*

**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b - 56122 Pisa

Tel. +39 050 7846500

[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

Internal Press Office

[press@calabughi.com](mailto:press@calabughi.com)

**Press Office - Spriano Communication & Partners**

Via Santa Radegonda, 16 - 20121 Milan

Tel. +39 02 83635708

Matteo Russo

[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)

Cristina Tronconi

[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)

**PharmaNutra S.p.A.**

Founded and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra, was established in 2003; with a national widespread presence and in more than 60 countries, it develops unique nutraceuticals and innovative medical devices, overseeing the entire production process from the proprietary raw materials to the finished product. PharmaNutra is the leading producer, with the SiderAL® trademark, of iron-based nutritional supplements, a field where it holds important patents on Sucrosomial® Technology, and is regarded as one of the top emerging players in medical devices for the rehabilitation of joint capacity thanks to the Cetilar brand.

Fine Comunicato n.20106-29

Numero di Pagine: 4